IL6 and COVID-19: Moreover, evidence from meta‐analyses of randomized clinical trials indicates that glucocorticoids and/or IL‐6 antagonists can reduce short‐term cardiovascular death in patients with severe COVID‐19.57, 58 Further research on large samples of patients is warranted to assess the specific impact of these therapies on COVID‐19‐associated AVB and related outcomes.